CLDX vs CUE
CLDX: A clinical-stage biopharmaceutical company developing mast cell-targeted monoclonal and bispecific antibodies for chronic urticaria, inflammatory skin diseases, and systemic inflammatory conditions. CUE: Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate anti-tumor immunity in cancer.
Side-by-side fundamentals
| Metric | CLDX | CUE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $34.77 | $34.20 | |
| Market cap as of 2026-07-23 | $2.7B | $144M | |
| PEG as of 2026-07-23 | -0.14 | n/a | |
| Net margin as of 2026-07-23 | -25011.8% | -59.6% | CUE higher |
| Gross margin as of 2026-07-23 | +17.6% | n/a | |
| Operating margin as of 2026-07-23 | -27187.6% | -59.9% | CUE higher |
| ROE as of 2026-07-23 | -50.7% | -98.3% | CLDX higher |
| ROA as of 2026-07-23 | -46.6% | -53.7% | CLDX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -88.5% | +309.6% | CUE higher |
| Revenue CAGR (3y) SEC XBRL | -13.1% | +180.5% | CUE higher |
| Beta as of 2026-07-23 | 0.82 | 2.49 | |
| 1-year return as of 2026-07-22 close | +55.5% | +26.3% | CLDX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.